Coya Therapeutics (NASDAQ:COYA) Earns Buy Rating from Analysts at HC Wainwright

HC Wainwright initiated coverage on shares of Coya Therapeutics (NASDAQ:COYA) in a report released on Monday morning, Marketbeat.com reports. The brokerage issued a buy rating and a $18.00 price objective on the stock. HC Wainwright also issued estimates for Coya Therapeutics’ Q3 2024 earnings at ($0.41) EPS, Q4 2024 earnings at ($0.43) EPS, FY2024 earnings at ($1.38) EPS, Q1 2025 earnings at ($0.42) EPS, Q2 2025 earnings at ($0.19) EPS, Q3 2025 earnings at ($0.43) EPS, Q4 2025 earnings at ($0.44) EPS and FY2025 earnings at ($1.48) EPS.

A number of other research analysts have also weighed in on the company. Chardan Capital reaffirmed a buy rating and set a $14.00 target price on shares of Coya Therapeutics in a report on Wednesday, June 5th. Rodman & Renshaw began coverage on shares of Coya Therapeutics in a report on Thursday, June 13th. They set a buy rating and a $18.00 target price on the stock.

Coya Therapeutics Stock Up 2.6 %

NASDAQ COYA opened at $6.22 on Monday. The firm has a market cap of $90.92 million, a P/E ratio of -7.32 and a beta of 0.58. The company’s 50 day moving average is $6.30 and its 200-day moving average is $7.55. Coya Therapeutics has a 12-month low of $3.21 and a 12-month high of $10.69.

Coya Therapeutics (NASDAQ:COYA) last issued its earnings results on Monday, August 12th. The company reported ($0.19) earnings per share (EPS) for the quarter. The business had revenue of $3.43 million for the quarter. Equities analysts expect that Coya Therapeutics will post -1.17 EPS for the current year.

Institutional Trading of Coya Therapeutics

Large investors have recently modified their holdings of the business. Renaissance Technologies LLC bought a new position in shares of Coya Therapeutics in the second quarter worth approximately $101,000. Gilbert & Cook Inc. bought a new position in shares of Coya Therapeutics in the 2nd quarter worth $61,000. Vanguard Group Inc. raised its position in shares of Coya Therapeutics by 772.3% during the 1st quarter. Vanguard Group Inc. now owns 847,490 shares of the company’s stock valued at $8,407,000 after buying an additional 750,338 shares in the last quarter. Greenlight Capital Inc. lifted its holdings in shares of Coya Therapeutics by 172.2% during the 4th quarter. Greenlight Capital Inc. now owns 1,274,026 shares of the company’s stock worth $9,441,000 after acquiring an additional 805,959 shares during the last quarter. Finally, AIGH Capital Management LLC grew its position in Coya Therapeutics by 92.6% in the fourth quarter. AIGH Capital Management LLC now owns 1,031,977 shares of the company’s stock worth $7,381,000 after acquiring an additional 496,183 shares in the last quarter. Institutional investors own 39.75% of the company’s stock.

About Coya Therapeutics

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.